We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Anxiety Depression and Rheumatoid Arthritis (ADAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03061877
Recruitment Status : Not yet recruiting
First Posted : February 23, 2017
Last Update Posted : April 26, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
Anxiety and depression are highly prevalent in people with rheumatoid arthritis (RA).This study is to investigate the effect of anxiety and depression on treatment response in people with RA using observational longitudinal study design.

Condition or disease Intervention/treatment
Rheumatoid Arthritis Other: Anxiety or depression

Study Design

Study Type : Observational
Estimated Enrollment : 134 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Anxiety and Depression on Treatment Response in Rheumatoid Arthritis
Anticipated Study Start Date : September 2017
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
Anxiety or depression Other: Anxiety or depression
The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
Non-anxiety or depression

Outcome Measures

Primary Outcome Measures :
  1. Clinical remission [ Time Frame: 6 months ]
    Clinical remission defined by the Disease Activity Score 28 (DAS28) with a score less than 2.6

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
People diagnosed with rheumatoid arthritis according to American College Rheumatology (ACR) criteria 2010

Inclusion Criteria:

  • People diagnosed with rheumatoid arthritis according to the American College Rheumatology (ACR) criteria 2010

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03061877

Contact: Kun Zou, PhD 86 028-87393972 zoukun.jy@outlook.com

Sponsors and Collaborators
Sichuan Provincial People's Hospital
Principal Investigator: Kun Zou, PhD Sichuan Provincial People's Hospital
More Information

Responsible Party: Kun Zou, PhD, Sichuan Provincial People's Hospital
ClinicalTrials.gov Identifier: NCT03061877     History of Changes
Other Study ID Numbers: SichuanPPH201701
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: April 26, 2017
Last Verified: April 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kun Zou, Sichuan Provincial People's Hospital:
Rheumatoid arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Behavioral Symptoms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases